Medacta Group's 9.7% Revenue Growth in H1 2026

Medacta Group SA announced impressive financial results for the first half of 2026. The company reported revenue growth of 9.7% in constant currency, reaching 368 million euros. Despite facing a weakening in the U.S. market, the firm achieved a robust adjusted EBITDA margin of 27.8% due to strong demand from new surgeons and effective cost management.

Key growth sectors included Asia Pacific and EMEA, which saw double-digit increases, while North America experienced a moderate rise of 6.6%. Latin America displayed exceptional growth at 16.4%, although from a smaller base. The company's focus on innovation, notably in hip and knee solutions, contributed significantly to this expansion.

Medacta's ongoing investments are poised to support future growth, including a new headquarters in Tennessee. The company's revenue growth target for 2026 is set between 10% and 14% in constant currency, underlining its resilient position in the market.